The GSK share price is 14% off its 52-week high. Time to consider buying?

The GSK share price has taken a tumble since peaking back in May. This Fool thinks now could be the time to take a closer look at the stock.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

At £15.59, GSK’s (LSE: GSK) share price is 14% lower than the 52-week high of £18.23 it hit back in May. I reckon now could be a good time to take a closer look at the FTSE 100 pharmaceutical giant.

It has been a volatile year for the stock. But as a long-term investor, if I sense a strong buying opportunity, I’m content with riding out some short-term ups and downs. With that, let’s dig a little deeper into GSK.

Created with Highcharts 11.4.3GSK PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

Short-term challenges

There’s one main reason I see that explains why its share price has fallen. It’s linked to potential litigation surrounding Zantac, a heartburn drug that was taken off shelves in 2019 after being linked to causing cancer.

Should you invest £1,000 in Rolls-Royce right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Rolls-Royce made the list?

See the 6 stocks

Earlier this year, a judge in Delaware ruled in favour of around 72,000 lawsuits related to Zantac and its link to cancer to go forward.

This came as a shock decision. When it was revealed, it wiped almost £7bn off GSK’s value in just one day. Its share price has failed to recover since.

GSK now faces the potential of thousands of costly court cases. That clearly has investors worried. Analysts at Citi have said it could cost the firm up to £3bn in settlement fees.

Long-term growth

But looking past that, what could drive long-term growth for the business? Well, I see plenty of encouraging factors.

Its Q2 update highlighted its growing R&D pipeline. The business has now secured approvals or filings for 10 “major opportunities”. It also reported “positive data” from seven phase III trials.

In its results, the business upgraded its 2024 guidance. Sales growth should now come in between 7-9%. Core operating profit growth should sit between 11-13%.

Attractive value

Looking at its price-to-earnings (P/E) ratio, the stock looks like good value for money. It trades on a P/E of 16. As the chart below highlights, that’s significantly cheaper than industry peers such as AstraZeneca, which trades on a P/E of 38.2.


Created with TradingView

To go with that, the stock has a healthy dividend yield of 3.8%. Not only is that higher than the FTSE 100 average (3.6%), but, as seen below, it’s also higher than AstraZeneca’s 1.8% yield.


Created with TradingView

My move

With the stock trading below its 52-week high, I think now could be a smart time for investors to take a closer look at GSK and consider buying some shares.

Despite the potential challenges it could face in the months ahead, I think there’s a lot to like about the business.

Legal complications are always a threat when investing in pharma stocks. And no doubt further negative updates relating to Zantac could send its share price down again.

However, it’s a stock with a solid valuation. Plus, as it carries on growing its pipeline, I think the business is well-positioned to post strong growth in the coming years. I’ll be delving deeper into the FTSE 100 constituent in the weeks ahead.

But this isn’t the only opportunity that’s caught my attention this week. Here are:

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Charlie Keough has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc and GSK. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

£10,000 invested in Apple shares last week is now worth…

Apple shares are down 18% over the past week. It’s a truly phenomenal downward movement, but investors may want to…

Read more »

Investing Articles

Are shares like Tesco a safe haven for investors?

Christopher Ruane sees a lot to like about Tesco shares. But does he see them as a safe heaven in…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

The 2025 stock market sell-off could be a once-in-a-decade opportunity to build wealth in an ISA

If a long-term investor has cash sitting in an investment ISA, now could be a good time to put some…

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

Is now a good time to start buying shares?

Stock market turbulence can be alarming, but it can also offer opportunity. Our writer considers whether now could be the…

Read more »

Investing Articles

Hunting for passive income? These falling insurance giants offer 10% yields

The UK insurance sector is typically a good place to look for attractive dividend yields. Dr James Fox details two…

Read more »

Investing Articles

Considering a Stocks and Shares ISA this April? Avoid these mistakes!

When opening a Stocks and Shares ISA for the first time, it's easy to fall foul of some costly mistakes.…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

With global markets down 10%+ investors should remember this legendary quote from Warren Buffett

Warren Buffett is the greatest investor of all time. And he says that the best time to buy shares is…

Read more »

Investing Articles

I asked ChatGPT for the best safe havens in the FTSE 100 amid Trump’s tariffs 

Our writer isn't convinced by the answers that AI assistant ChatGPT rattled off when asked about solid FTSE 100 defensive…

Read more »